Scholarlink

Purpose <p>To evaluate whether oral Age-Related Eye Disease Study (AREDS/2) supplementation is associated with structural or functional disease progression over 24 months in patients with Macular Telangiectasia Type 2 (MacTel).</p> Methods <p>This post hoc analysis included 208 participants enrolled in two 24-month Phase 3 clinical trials of revakinagene taroretcel-lwey for MacTel (sham,&#xa0;<i>n</i>&#xa0;= 98; treated,&#xa0;<i>n</i>&#xa0;= 110). Consistent AREDS/2 exposure was defined by documented intake at baseline and month 24. The primary outcome was 24-month change in ellipsoid zone (EZ) area loss. Secondary outcomes included changes in reading speed, best-corrected visual acuity (BCVA), and aggregate retinal sensitivity. Non-randomized exposure was adjusted using a doubly robust framework combining inverse probability of treatment weighting (IPTW) and multivariable survey-weighted linear regression.</p> Results <p>In the sham cohort, AREDS/2 supplementation was not associated with statistically significant differences in 24-month EZ area loss (<i>P</i>&#xa0;= 0.258). In the treated cohort, an initial association with greater EZ area loss among AREDS/2 users (<i>P</i> = 0.032) became non-significant after full multivariable adjustment for age, sex, and diabetes status (<i>P</i>&#xa0;= 0.577). Secondary functional metrics showed no significant differences between groups across either cohort. </p> Conclusions <p>AREDS/2 supplementation was not associated with meaningful differences in structural or functional MacTel progression over a 24-month period. These findings do not provide evidence that routine AREDS/2 supplementation slows EZ area loss or preserves visual function in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between AREDS/2 supplementation and structural and functional progression in macular telangiectasia type 2

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月21日

查看全文
  • Kensington Hatcher,
  • Thomas Aaberg Jr.,
  • Muna Bitar,
  • David Sarraf

摘要

Purpose

To evaluate whether oral Age-Related Eye Disease Study (AREDS/2) supplementation is associated with structural or functional disease progression over 24 months in patients with Macular Telangiectasia Type 2 (MacTel).

Methods

This post hoc analysis included 208 participants enrolled in two 24-month Phase 3 clinical trials of revakinagene taroretcel-lwey for MacTel (sham, n = 98; treated, n = 110). Consistent AREDS/2 exposure was defined by documented intake at baseline and month 24. The primary outcome was 24-month change in ellipsoid zone (EZ) area loss. Secondary outcomes included changes in reading speed, best-corrected visual acuity (BCVA), and aggregate retinal sensitivity. Non-randomized exposure was adjusted using a doubly robust framework combining inverse probability of treatment weighting (IPTW) and multivariable survey-weighted linear regression.

Results

In the sham cohort, AREDS/2 supplementation was not associated with statistically significant differences in 24-month EZ area loss (P = 0.258). In the treated cohort, an initial association with greater EZ area loss among AREDS/2 users (P = 0.032) became non-significant after full multivariable adjustment for age, sex, and diabetes status (P = 0.577). Secondary functional metrics showed no significant differences between groups across either cohort.

Conclusions

AREDS/2 supplementation was not associated with meaningful differences in structural or functional MacTel progression over a 24-month period. These findings do not provide evidence that routine AREDS/2 supplementation slows EZ area loss or preserves visual function in this population.